Guojun Hou

Dr. Guojun Hou

School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GHGuojun Hou
Guojun Hou
IHIsaac TW Harley
Isaac TW Harley
XLXiaoming Lu
Xiaoming Lu
TZTian Zhou
Tian Zhou
NXNing Xu
Ning Xu
NSNan Shen
Nan Shen
Since most variants that impact polygenic disease phenotypes localize to non-coding genomic regions, understanding the consequences of regulatory element variants will advance understanding of human disease mechanisms. Here, we report that the systemic lupus erythematosus (SLE) risk variant rs2431697 as likely causal for SLE through disruption of a regulatory element, modulating miR-146a expression. Using epigenomic analysis, genome-editing and 3D chromatin structure analysis, we show that rs2431697 tags a cell-type dependent distal enhancer specific for miR-146a that physically interacts with the miR-146a promoter. NF-kB binds the disease protective allele in a sequence-specific manner, increasing expression of this immunoregulatory microRNA. Finally, CRISPR activation-based modulation of this enhancer in the PBMCs of SLE patients attenuates type I interferon pathway activation by increasing miR-146a expression. Our work provides a strategy to define non-coding RNA functional regulatory elements using disease-associated variants and provides mechanistic links between autoimmune disease risk genetic variation and disease etiology.

6 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TZTian Zhou
Tian Zhou
XZXinyi Zhu
Xinyi Zhu
ZYZhizhong Ye
Zhizhong Ye
YWYong-Fei Wang
Yong-Fei Wang
CYChao Yao
Chao Yao
NSNan Shen
Nan Shen
Despite strong evidence that human genetic variants affect the expression of many key transcription factors involved in autoimmune diseases, establishing biological links between non-coding risk variants and the gene targets they regulate remains a considerable challenge. Here, we combine genetic, epigenomic, and CRISPR activation approaches to screen for functional variants that regulate IRF8 expression. We demonstrate that the locus containing rs2280381 is a cell-type-specific enhancer for IRF8 that spatially interacts with the IRF8 promoter. Further, rs2280381 mediates IRF8 expression through enhancer RNA AC092723.1, which recruits TET1 to the IRF8 promoter regulating IRF8 expression by affecting methylation levels. The alleles of rs2280381 modulate PU.1 binding and chromatin state to regulate AC092723.1 and IRF8 expression differentially. Our work illustrates an integrative strategy to define functional genetic variants that regulate the expression of critical genes in autoimmune diseases and decipher the mechanisms underlying the dysregulation of IRF8 expression mediated by lupus risk variants.

10 April 2024 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
XZXinyi Zhu
Xinyi Zhu
YCYashuo Chen
Yashuo Chen
ZYZhihua Yin
Zhihua Yin
YZYutong Zhang
Yutong Zhang
YSYiwei Shen
Yiwei Shen
GHGuojun Hou
Guojun Hou
Objectives Systemic lupus erythematosus (SLE) is a highly heterogeneous disease, and B cell abnormalities play a central role in the pathogenesis of SLE. Long non-coding RNAs (lncRNAs) have also been implicated in the pathogenesis of SLE. The expression of lncRNAs is finely regulated and cell-type dependent, so we aimed to identify B cell-expressing lncRNAs as biomarkers for SLE, and to explore their ability to reflect the status of SLE critical pathway and disease activity. Methods Weighted gene coexpression network analysis (WGCNA) was used to cluster B cell-expressing genes of patients with SLE into different gene modules and relate them to clinical features. Based on the results of WGCNA, candidate lncRNA levels were further explored in public bulk and single-cell RNA-sequencing data. In another independent cohort, the levels of the candidate were detected by RT-qPCR and the correlation with disease activity was analysed. Results WGCNA analysis revealed one gene module significantly correlated with clinical features, which was enriched in type I interferon (IFN) pathway. Among non-coding genes in this module, lncRNA RP11-273G15.2 was differentially expressed in all five subsets of B cells from patients with SLE compared with healthy controls and other autoimmune diseases. RT-qPCR validated that RP11-273G15.2 was highly expressed in SLE B cells and positively correlated with IFN scores (r=0.7329, p<0.0001) and disease activity (r=0.4710, p=0.0005). Conclusion RP11-273G15.2 could act as a diagnostic and disease activity monitoring biomarker for SLE, which might have the potential to guide clinical management.

27 July 2023 in Biology
Verified
Journal Article
Open access
PDF file
ZYZihang Yin
Zihang Yin
SCShuang Cui
Shuang Cui
SXSong Xue
Song Xue
YXYufan Xie
Yufan Xie
YWYefan Wang
Yefan Wang
YGYa Guo
Ya Guo
Three-dimensional genome organization has been increasingly recognized as an important determinant of the precise regulation of gene expression in mammalian cells, yet the relationship between gene transcriptional activity and spatial subcompartment positioning is still not fully comprehended. Here, we first utilized genome-wide Hi-C data to infer eight types of subcompartment (labeled A1, A2, A3, A4, B1, B2, B3, and B4) in mouse embryonic stem cells and four primary differentiated cell types, including thymocytes, macrophages, neural progenitor cells, and cortical neurons. Transitions of subcompartments may confer gene expression changes in different cell types. Intriguingly, we identified two subsets of subcompartments defined by higher gene density and characterized by strongly looped contact domains, named common A1 and variable A1, respectively. We revealed that common A1, which includes highly expressed genes and abundant housekeeping genes, shows a ~2-fold higher gene density than the variable A1, where cell type-specific genes are significantly enriched. Thus, our study supports a model in which both types of genomic loci with constitutive and regulatory high transcriptional activity can drive the subcompartment A1 formation. Special chromatin subcompartment arrangement and intradomain interactions may, in turn, contribute to maintaining proper levels of gene expression, especially for regulatory non-housekeeping genes.

15 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
GHGuojun Hou
Guojun Hou
IHIsaac T.W. Harley
Isaac T.W. Harley
XLXiaoming Lu
Xiaoming Lu
TZTian Zhou
Tian Zhou
NXNing Xu
Ning Xu
NSNan Shen
Nan Shen
The human genome contains millions of putative regulatory elements, which regulate gene expression. We are just beginning to understand the functional consequences of genetic variation within these regulatory elements. Since the bulk of common genetic variation impacting polygenic disease phenotypes localizes to these non-coding regions of the genome, understanding the consequences will improve our understanding of the mechanisms mediating genetic risk in human disease. Here, we define the systemic lupus erythematosus (SLE) risk variant rs2431369 as likely causal for SLE and show that it is located in a functional regulatory element that modulates miR-146a expression. We use epigenomic analysis and genome-editing to show that the rs2431697-containing region is a distal enhancer that specifically regulates miR-146a expression in a cell-type dependent manner. 3D chromatin structure analysis demonstrates physical interaction between the rs2431697-containing region and the miR-146a promoter. Further, our data show that NF-kB binds the disease protective allele in a sequence-specific manner, leading to increased expression of this immunoregulatory microRNA. Our work provides a strategy for using disease-associated variants to define the functional regulatory elements of non-coding RNA molecules such as miR-146a and provides mechanistic links between autoimmune disease risk genetic variation and disease etiology.

13 November 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
XYXiang Yu
Xiang Yu
LWLi Wang
Li Wang
ZHZhijun Han
Zhijun Han
CYChao Yao
Chao Yao
RQRong Qiu
Rong Qiu
YTYuanjia Tang
Yuanjia Tang
Summary: It is well known that some pathogenic cells have enhanced glycolysis, the regulatory network leading to increased glycolysis are not well characterized. Here, we show that pathogenic T H 17 cells specifically upregulate glycolytic pathway genes compared to homeostatic T H 17 cells. Bioenergetic assay and metabolomics analyses indicate that pathogenic T H 17 cells are highly glycolytic compared to nonpathogenic T H 17 cells. Chromatin landscape analyses demonstrate T H 17 cells in vivo show distinct chromatin states, and pathogenic T H 17 cells show enhanced chromatin accessibility at glycolytic genes with NF-kB binding sites. Mechanistic studies reveal that TGF-β1 signaling induces T H 17 cell chromatin remodeling and represses c-Rel-mediated glycolysis. A miR-21-Peli1 -c-Rel loop was further identified to be essential for glycolysis of pathogenic T H 17 cells. These findings extend our understanding of the regulation T H 17 cell glycolysis in vivo and provide insights for future therapeutic intervention to T H 17 cell mediated autoimmune diseases.